Best Stocks Under $1.00 for 2018

The stock market has had an incredible bull-run since the Great Recession of 2008 and 2009. Stocks continue to hit new all-time highs and the price-to-earnings ratios of most S&P 500 companies look very expensive. Many investors are having trouble finding low-priced stocks that haven't already appreciated greatly during the last decade. It's hard to find a good deal on Wall Street right now when even small S&P 500 companies are trading at market caps above $1 billion.

Stocks have gotten expensive both in-terms of share price and their valuation relative to earnings. In more normal markets, a typical S&P 500 company has traded at about fifteen times their earnings. Most stocks are currently trading closer to 25 times their annual earnings. While the stock market has become more expensive as a whole, there are still a handful of undervalued stocks that are trading at less than $1.00 per share.

Value investing opportunities do exist if you're looking in the right places. Putting together a list of the best stocks under $1.00 requires investors to look at smaller and riskier companies and in sectors that are either undiscovered or unloved by the market as a whole. Some of these cheap stocks may not look especially attractive today, but long-term investors will profit if they are willing to exercise patience and hold on to shares of these comapnies through multiple economic cycles.

Some of these companies are solid investing ideas because they are too little and considered too risky to attract the interest of most managed mutual funds and Wall Street money managers. Others operate in unloved and untested areas of the market. You may find even find crypto stocks, marijuana stocks and bitcoin stocks on this list. Others have been beat up by Mr. Market after a long period of slowing profits, but are now actively trying to turn around their business and bounce back. These low-priced stocks operate in a lot of different industries, but these picks all carry two common characteristics. They all have a super-low share price of $1.00 or less and consisently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts.

#1 - Capstone Turbine (NASDAQ:CPST)

Stock Price: $0.64
Market Cap: $44.88 million
P/E Ratio: -3.2
Consensus Rating: Buy
Ratings Breakdown: 4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $2.3750 (271.1% Upside)

Capstone Turbine logoCapstone Turbine Corporation develops, manufactures, markets, and services microturbine technology solutions for use in stationary distributed power generation applications worldwide. It offers microturbine units, components, and various accessories for applications, including cogeneration comprising combined heat and power (CHP) and integrated CHP, as well as combined cooling, heat, and power; and renewable energy, natural resources, and critical power supply. The company's microturbines are also used as battery charging generators for hybrid electric vehicle applications. It also provides various accessories, including rotary gas compressors with digital controls; heat recovery modules for CHP applications; dual mode controllers that allow automatic transition between grid connect and stand-alone modes; batteries with digital controls for stand-alone or dual-mode operations; batteries with digital controls; power servers for multipacked installations; protocol converters for Internet access; packaging options; and miscellaneous parts, such as frames, exhaust ducting, backflow dampers, and installation hardware. In addition, the company remanufactures microturbine engines; and provides after-market parts and services. It markets and sells its products primarily through distributors and original equipment manufacturers. Capstone Turbine Corporation was founded in 1988 and is headquartered in Van Nuys, California.
#2 - SCYNEXIS (NASDAQ:SCYX)

Stock Price: $0.49
Market Cap: $24.94 million
P/E Ratio: -0.5
Consensus Rating: Buy
Ratings Breakdown: 7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $5.2857 (978.7% Upside)

SCYNEXIS logoSCYNEXIS, Inc., a drug development company, develops and commercializes anti-infectives to address unmet therapeutic needs. It is developing its lead product candidate, SCY-078, as a novel oral and intravenous drug for the treatment of various fungal infections, including serious and life-threatening invasive fungal infections. The company also develops SCY-078, which is in various Phase I studies for the oral and intravenous formulations, as well as has completed Phase II study as a step-down therapy in patients with invasive candidiasis and vulvovaginal candidiasis. It has research collaborations with Merck Sharp & Dohme Corp. and R-Pharm, CJSC, to develop and commercialize rights for SCY-078. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was founded in 1999 and is headquartered in Jersey City, New Jersey.
#3 - Histogenics (NASDAQ:HSGX)

Stock Price: $0.55
Market Cap: $32.10 million
P/E Ratio: -0.6
Consensus Rating: Buy
Ratings Breakdown: 4 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $3.3750 (515.3% Upside)

Histogenics logoHistogenics Corporation, a clinical-stage company, focuses on the development of restorative cell therapies in the United States. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. It has an exclusive channel collaboration agreement with Intrexon Corporation for the development and commercialization of allogeneic genetically modified chondrocyte cell therapeutics for the treatment or repair of damaged articular hyaline cartilage in humans. Histogenics Corporation was founded in 2000 and is headquartered in Waltham, Massachusetts.
#4 - Agile Therapeutics (NASDAQ:AGRX)

Stock Price: $0.74
Market Cap: $28.27 million
P/E Ratio: -0.8
Consensus Rating: Buy
Ratings Breakdown: 5 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $3.75 (406.8% Upside)

Agile Therapeutics logoAgile Therapeutics, Inc., a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch, which completed Phase III clinical trials. The company is also developing a pipeline of other transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter lighter periods; AG200-ER (SmP), a regimen to allow a woman to extend the length of her cycle, as well as experience shorter and lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was founded in 1997 and is headquartered in Princeton, New Jersey.
#5 - Eclipse Resources (NYSE:ECR)

Stock Price: $0.95
Market Cap: $301.90 million
P/E Ratio: -23.8
Consensus Rating: Buy
Ratings Breakdown: 4 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $1.85 (94.1% Upside)

Eclipse Resources logoEclipse Resources Corporation, an independent exploration and production company, acquires and develops oil and natural gas properties in the Appalachian Basin. The company holds interests in the Utica Shale and Marcellus Shale areas. As of December 31, 2017, it had an acreage position approximately covering an area of 203,000 net acres in Eastern Ohio. The company's estimated proved reserves were 1,458.6 billion cubic feet of natural gas equivalent. Eclipse Resources Corporation was founded in 2011 and is headquartered in State College, Pennsylvania.
#6 - ConforMIS (NASDAQ:CFMS)

Stock Price: $0.52
Market Cap: $31.89 million
P/E Ratio: -0.4
Consensus Rating: Buy
Ratings Breakdown: 5 Buy Ratings, 0 Hold Ratings, 1 Sell Ratings.
Consensus Price Target: $2.8750 (452.9% Upside)

ConforMIS logoConforMIS, Inc., a medical technology company, develops, manufactures, and sells joint replacement implants. The company offers customized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a customized bicompartmental knee replacement system; and iUni, a customized unicompartmental knee replacement product to treat the medial or lateral compartment of the knee. It also provides ConforMIS Hip System, a hip replacement product; and iJigs, a customized single-use patient-specific instrumentation. The company markets and sells its products to hospitals and other medical facilities through sales force, independent sales representatives, and distributors in the United States, Germany, the United Kingdom, Austria, Ireland, Switzerland, Singapore, Hong Kong, Malaysia, and Monaco. ConforMIS, Inc. was founded in 2004 and is headquartered in Billerica, Massachusetts.
#7 - Trevena (NASDAQ:TRVN)

Stock Price: $0.58
Market Cap: $50.10 million
P/E Ratio: -0.5
Consensus Rating: Buy
Ratings Breakdown: 3 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $6.35 (993.5% Upside)

Trevena logoTrevena, Inc., a biopharmaceutical company, develops therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. Its product candidates include OLINVO injection, a G protein biased ligand of the µ opioid receptor that has completed Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is preferred; TRV250, a G protein biased ligand targeting the d-receptor, which is in Phase I clinical study for the treatment of migraine; and TRV734, a small molecule G protein biased ligand of the µ opioid receptor that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain, as well as TRV027 for the treatment of acute heart failure. The company was founded in 2007 and is headquartered in Chesterbrook, Pennsylvania.
#8 - Flex Pharma (NASDAQ:FLKS)

Stock Price: $0.40
Market Cap: $7.43 million
P/E Ratio: -0.2
Consensus Rating: Hold
Ratings Breakdown: 2 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $17.50 (4,253.2% Upside)

Flex Pharma logoFlex Pharma, Inc. operates as a biotechnology company. It engages in developing treatments for exercise-associated muscle cramps, nocturnal leg cramps and spasms associated with severe neuromuscular conditions. The company operates through the following business segments: Consumer Operations and Drug Development. The Consumer Operations segment includes HOTSHOT product and consumer operations. The Drug Development segment engages in the development of innovative and proprietary drug products to treat muscle cramps and spasms associated with severe neurological conditions. Flex Pharma was founded by Christoph Westphal and Jennifer M. Cermak on February 26, 2014 and is headquartered in Boston, MA.
#9 - Gemphire Therapeutics (NASDAQ:GEMP)

Stock Price: $0.90
Market Cap: $12.84 million
P/E Ratio: -0.3
Consensus Rating: Hold
Ratings Breakdown: 2 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $20.20 (2,144.7% Upside)

Gemphire Therapeutics logoGemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and non-alcoholic steatohepatitis (NASH). It is developing gemcabene, a novel, once-daily, oral therapy, for high risk cardiovascular patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies, primarily statin therapy, and for those patients who present with NASH. The company was founded in 2008 and is headquartered in Livonia, Michigan.
#10 - Trican Well Service (OTCMKTS:TOLWF)

Stock Price: $0.91
Consensus Rating: Hold
Ratings Breakdown: 2 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: N/A

Trican Well Service logoTrican Well Service Ltd., an oilfield services company, provides various specialized products, equipment, services, and technology for use in the drilling, completion, stimulation, and reworking of oil and gas wells primarily in Canada. It offers cementing solutions, including pre-flushes and spacers, cement plugs, lost circulation, gas migration prevention, cement design solutions, and laboratory solutions, as well as surface, intermediate, production, liner, horizontal, and remedial/squeeze cementing services; and cement pumpers, bulk equipment, and cement auxiliary equipment. The company also provides geological solutions comprising education and studies, and lab and field services; reservoir solutions, including exploration, production analysis, and simulation and modeling services; acidizing and production enhancement services, such as production and injection well enhancement services, and equipment; and coiled tubing solutions that include coiled tubing fracturing, specially designed tools, well cleanouts, milling, high pressure jetting, e-coil (smart coil), in-house engineering, nitrogen gas lifting, and production enhancement, as well as equipment and tools. In addition, it offers industrial services, such as chemical, mechanical, and bundle cleaning services, as well as nitrogen services; pipeline services, such as commissioning, operating, and abandonment services; fracturing solutions and equipment; and multistage fracturing and well intervention tools. Trican Well Service Ltd. was founded in 1979 and is headquartered in Calgary, Canada.
#11 - THOMAS COOK GRP/ADR (OTCMKTS:TCKGY)

Stock Price: $0.67
Market Cap: $537.55 million
P/E Ratio: 2.8
Dividend Yield: 2.12 %
Consensus Rating: Hold
Ratings Breakdown: 3 Buy Ratings, 2 Hold Ratings, 1 Sell Ratings.
Consensus Price Target: N/A

THOMAS COOK GRP/ADR logoThomas Cook Group plc provides leisure travel services in the United Kingdom, Continental Europe, Northern Europe, and Germany. The company operates through Group Tour Operator and Group Airline segments. It owns, manages, or franchises 190 own-brand hotels in 16 countries under the Casa Cook, Sunwing, Sunprime, Sunconnect, Sentido, Smartline, and Aldiana brands, as well as partner hotels. The company also operates an airline fleet of 93 aircrafts; and Academy of Excellence, which offers professional training and consulting packages, including mystery checks and quality audits, online reputation services, quality initiative, and individual training, and coaching and consulting packages for partner hotels. In addition, it provides ancillary products, including extra luggage, seat reservations, in-resort transfers, and room upgrades; tour operations and associated services; and scheduled and charter, and related services. The company offers its products through its Website and retail stores, as well as third party retail channels. Thomas Cook Group plc was founded in 1841 and is based in London, the United Kingdom.
#12 - Weatherford International (NYSE:WFT)

Stock Price: $0.43
Market Cap: $466.53 million
P/E Ratio: -0.4
Consensus Rating: Hold
Ratings Breakdown: 9 Buy Ratings, 9 Hold Ratings, 4 Sell Ratings.
Consensus Price Target: $3.2874 (656.9% Upside)

Weatherford International logoWeatherford International plc operates as a multinational oilfield service company worldwide. It offers equipment and services used in the drilling, evaluation, completion, production, and intervention of oil and natural gas wells. The company operates in two segments, Western Hemisphere and Eastern Hemisphere. It offers artificial-lift systems, including reciprocating rod, progressing cavity pumping, gas, hydraulic, plunger, and hybrid lift systems, as well as related automation and control systems; pressure pumping and reservoir stimulation services, such as acidizing, fracturing and fluid systems, cementing, and coiled-tubing intervention; and drill stem test tools, and surface well testing and multiphase flow measurement services. The company also provides safety, down hole reservoir monitoring, flow control, and multistage fracturing systems; sand-control technologies, and production and isolation packers for maximum production with minimal cost; liner hangers to suspend a casing string in high-temperature and high-pressure wells; cementing products, including plugs, float and stage equipment, and torque-and-drag reduction technology to operators for zonal isolation; and pre-job planning and installation services. In addition, it offers directional, and logging and measurement while drilling systems; rotary-steerable systems; high-temperature and high-pressure sensors, drilling reamers, and circulation subs; managed pressure drilling, conventional mud-logging, drilling instrumentation, gas analysis, well site consultancy, open hole and cased-hole logging services; reservoir solutions and software products; and remediation services. Further, the company provides equipment and drilling tools; tubular handling, management, and connection services; equipment rental services; and onshore contract drilling and related services, as well as operates a fleet of land drilling and work over rigs. The company was founded in 1972 and is headquartered in Baar, Switzerland.
#13 - Celldex Therapeutics (NASDAQ:CLDX)

Stock Price: $0.25
Market Cap: $44.46 million
P/E Ratio: -0.3
Consensus Rating: Hold
Ratings Breakdown: 1 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $2.6667 (975.3% Upside)

Celldex Therapeutics logoCelldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of various immunotherapy technologies and other cancer-targeting biologics. Its drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer; and CDX-3379, a human monoclonal antibody that is in Phase II study in combination with cetuximab for the treatment of head and neck squamous cell carcinoma. The company also develops earlier stage drug candidates that are in clinical development, including CDX-014, an antibody-drug conjugate targeting renal and ovarian cancers; CDX-1140, a human monoclonal antibody; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-1401, an immunotherapeutic aimed at antigen presenting cells for cancer indications. Celldex Therapeutics, Inc. has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; University of Southampton; Amgen Inc.; Amgen Fremont; Seattle Genetics, Inc.; Yale University; and MedImmune, LLC. The company is headquartered in Hampton, New Jersey.
#14 - Ideal Power (NASDAQ:IPWR)

Stock Price: $0.26
Market Cap: $3.43 million
P/E Ratio: -0.3
Consensus Rating: Hold
Ratings Breakdown: 1 Buy Ratings, 5 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $1.6667 (541.0% Upside)

Ideal Power logoIdeal Power Inc. develops power conversion solutions with a focus on solar and storage, microgrid, and stand-alone energy storage applications. It operates through two Divisions, Power Conversion Systems and B-TRAN. The Power Conversion Systems Division focuses on its Power Packet Switching Architecture technology. The B-TRAN Division develops its Bi-directional bi-polar junction TRANsistor solid state switch technology. The company's principal products include 30-kilowatt(kW) power conversion systems, such as two-port and multi-port products. It also offers 30kW SunDial, a PV string inverter, which is field upgradable through the addition of a drop-in second DC port to connect batteries to a solar PV array; and The SunDial Plus, such as the PV inverter and the second DC battery port. The company sells its products primarily to systems integrators in the United States. The company was formerly known as Ideal Power Converters Inc. and changed its name to Ideal Power Inc. in July 2013. Ideal Power Inc. was founded in 2007 and is headquartered in Austin, Texas.
#15 - Synergy Pharmaceuticals (NASDAQ:SGYP)

Stock Price: $0.08
Market Cap: $32.29 million
P/E Ratio: -0.1
Consensus Rating: Hold
Ratings Breakdown: 1 Buy Ratings, 6 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $8.50 (10,525.0% Upside)

Synergy Pharmaceuticals logoSynergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. Its lead product is plecanatide, a novel uroguanylin based gastrointestinal platform that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome. The company also develops dolcanatide to treat mild-to-moderate ulcerative colitis. It has a licensing agreement with Cipher Pharmaceuticals Inc. to develop, market, distribute, and sell TRULANCE in Canada. Synergy Pharmaceuticals Inc. is headquartered in New York, New York.
#16 - Enterprise GP (NYSE:EPE)

Stock Price: $0.81
Market Cap: $241.01 million
P/E Ratio: -2.1
Consensus Rating: Hold
Ratings Breakdown: 1 Buy Ratings, 7 Hold Ratings, 1 Sell Ratings.
Consensus Price Target: $2.7222 (238.2% Upside)

Enterprise GP logoEP Energy Corporation, an independent exploration and production company, engages in the exploration for and the acquisition, development, and production of oil, natural gas, and natural gas liquids in the United States. The company has interests in three primary areas, such as the Permian basin in West Texas; the Eagle Ford Shale in South Texas; and the Altamont Field in the Uinta basin in Northeastern Utah. As of December 31, 2017, it had proved reserves of 392.1 million barrels of oil equivalent and had average net daily production of 82,257 barrel of oil equivalent/per day. The company primarily sells its oil and natural gas production to third parties. EP Energy Corporation was founded in 2013 and is headquartered in Houston, Texas.
#17 - Endologix (NASDAQ:ELGX)

Stock Price: $0.70
Market Cap: $70.70 million
P/E Ratio: -1.5
Consensus Rating: Hold
Ratings Breakdown: 1 Buy Ratings, 4 Hold Ratings, 1 Sell Ratings.
Consensus Price Target: $3.40 (385.6% Upside)

Endologix logoEndologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. It offers minimally-invasive endovascular repair (EVAR) products, including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the ovation abdominal stent graft system. The company also provides endovascular sealing (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens. In addition, it offers proximal aortic extensions and limb extensions which allows physicians to customize the implant to fit the patient's anatomy; and accessories to facilitate the delivery of its EVAR and EVAS products, including compatible guidewires, inflation devices, and snares. The company offers its EVAR products under Ovation, Powerlink System, IntuiTrak, AFX, VELA Proximal Endograft brand names; and EVAS products under the Nellix EVAS system brand name. It sells its products through direct sales force, network of agents, and independent distributors or agents. The company was formerly known as Radiance Medical Systems, Inc. and changed its name to Endologix, Inc. in May 2002. Endologix, Inc. was founded in 1992 and is headquartered in Irvine, California.
#18 - GASTAR EXPL INC/SH (NYSEAMERICAN:GST)

Stock Price: $0.06
Consensus Rating: Hold
Ratings Breakdown: 2 Buy Ratings, 2 Hold Ratings, 2 Sell Ratings.
Consensus Price Target: $1.0325 (1,740.5% Upside)

GASTAR EXPL INC/SH logoGastar Exploration Inc., an independent energy company, engages in the exploration, development and production of oil, condensate, natural gas, and natural gas liquids in the United States. Its principal activities include the identification, acquisition, exploration, and development of oil and natural gas properties on unconventional reserves, such as shale resource plays. The company holds interests in the oil and natural gas-rich reservoirs, including the Oswego limestone, Meramec, and Osage bench formations within the Mississippi Lime; and the Woodford shale formations. As of February 28, 2018, its principal assets included the STACK play covering approximately 67,800 net acres located in the Mid-Continent area of the United States. The company was formerly known as Gastar Exploration Ltd. and changed its name to Gastar Exploration Inc. in January 2014. Gastar Exploration Inc. is based in Houston, Texas.
#19 - Jones Energy (NYSE:JONE)

Stock Price: $0.83
Market Cap: $10.95 million
P/E Ratio: -0.1
Consensus Rating: Hold
Ratings Breakdown: 1 Buy Ratings, 3 Hold Ratings, 1 Sell Ratings.
Consensus Price Target: $18.00 (2,068.9% Upside)

Jones Energy logoJones Energy, Inc., an independent oil and gas company, engages in the acquisition, exploration, development, and production of oil and natural gas properties in the mid-continent United States. It owns leasehold interests in oil and natural gas producing properties, as well as in undeveloped acreage located in the Anadarko Basin in Oklahoma and Texas. As of December 31, 2017, the company's total estimated proved reserves included 104.8 million barrels of oil equivalent. Jones Energy, Inc. was founded in 1988 and is headquartered in Austin, Texas.
#20 - Premier Oil (OTCMKTS:PMOIY)

Stock Price: $0.95
Market Cap: $783.35 million
Consensus Rating: Hold
Ratings Breakdown: 1 Buy Ratings, 3 Hold Ratings, 1 Sell Ratings.
Consensus Price Target: N/A

Premier Oil logoPremier Oil plc, an oil and gas company, engages in the exploration, production, and development of oil and gas properties primarily in the Falkland Islands, Indonesia, Pakistan, the United Kingdom, Vietnam, and internationally. As of December 31, 2017, it had proven and probable reserves (2P) of 302 million barrels of oil equivalent (mmboe); and 2P reserves and 2C resources of 902 mmboe. Premier Oil plc was founded in 1934 and is headquartered in London, the United Kingdom.

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel